

REMARKS

Claims 1, 55-57, 71-78 and 123-125 were pending in the present application. Applicants have canceled claims 1, 55-57, 71-78 and 123-125 without prejudice and introduced new claims 126-145, which are directed to pharmaceutical composition comprising substantially pure Form F and pharmaceutically acceptable carrier or diluent.

Support for new claims 126-145 can be found, *inter alia*, on page 2, lines 14-24 and page 32, line 25-36 of the original specification. Therefore, new claims 126-145 are fully supported by the original specification and do not raise any issue of new matter. Accordingly, entry of the present preliminary amendment is respectfully requested. Upon entry of the present preliminary amendment, claims 126-145 will be under examination.

CONCLUSION

Applicants respectfully request entry of the present preliminary amendment and favorable consideration of all pending claims.

It is believed that no fee is deemed necessary in connection with the filing of the present preliminary amendment. However, if any fees are required, the Commissioner is hereby authorized to charge any such fees to our Deposit Account No. 16-1445.

Date: 04/29/05

Respectfully submitted,

Lance Y. Liu

Lance Y. Liu

Attorney for Applicant(s)

Reg. No. 45,379

Customer No. 28523

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 686-1652